TECHNOLOGY FOCUS - ELECTRICAL POWER AND ENERGY - Preferred Cell: The biofuel cell further comprises an electrode; a biocatalyst; a fuel source; and a membrane.    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preparation (claimed): The self-assembling peptide having amino acid pairing properties involves designing a peptide consisting of amino acids that are capable of at least one of hydrogen bonding, electrostatic interaction, hydrophobic interaction, and van der Waal's interaction with a complementary amino acid; and generating the peptide from two to forty amino acids in length consisting of at least one amino acid pair capable of at least one of hydrogen bonding, electrostatic interaction, hydrophobic interaction, and van der Waal's interaction, and having complementary amino acid pairing and stereochemistry with a second peptide. Preferred peptide: In the peptide (P1), the hydrogen bonding occur between side chains of complementary amino acids. The complementary peptides assemble in one of parallel or anti-parallel conformation. The peptides further assemble as one of end-to-end or staggered peptide arrangement. The peptides are assembled in staggered arrangement and at least one to 20 amino acids in the peptide form hydrogen bonds with complementary amino acids in a second peptide. The hydrogen bonding proton donor amino acid is selected from Arg, Trp, Tyr, Lys, His, Asp, Thr, Cys, Ser, Asn, Glu or Gln. The hydrogen bonding proton acceptor amino acid is selected from Arg, Trp, Tyr, Lys, His, Asp, Thr, Cys, Ser, Asn, Glu, Met or Gln. The hydrogen bonding amino acid is non-charged. The self-complementary beta -strand peptide is of formula (A1xB1yC1z)wA1z (Ia), (A1xB1yC1z)w(C'xB'yA'z)w (IIa), A3xB3yC3z... (III) or A4xB4yC3z...C4zB4yA4x (IV). The peptide further comprises a functional moiety at, at least one of an N-terminus and C-terminus of the peptide, where the functional moiety is selected from cell targeting moiety, a metal ion binding motif, or a cell membrane penetration moiety. The amino acids are selected from naturally occurring amino acids, D-amino acids, beta amino acid derivatives, or gamma amino acid derivatives. The self-complementary beta -strand peptide (P2) assembles in one of parallel or anti-parallel conformation. The peptide (P2) is of formula (A1w'B1x'A1y'C1z')nA1aB1b (V) (V). The hydrophobic amino acid is selected from Val, Ile, Leu, Met, Phe, Trp, Cys, Ala, Tyr, His, Thr, Ser, Pro, Gly, Arg or Lys. The charged amino acid is selected from the His, Arg, Lys, Asp or Glu. The hydrogen bonding amino acid is selected from a proton donor and a proton acceptor. The peptide further comprises at least one pi pairing amino acid selected from Tyr, Phe or Trp. The peptide is made of glutamic acid (E), alanine (A), phenyl alanine or lysine (K) residues i.e. EAK or EFK residues (i.e. EAK16-I, EFK16-II or EAK16-II). The amino acids are independently self-complementary and independently complementary to a non-self amino acid, and self-assembles into parallel beta -sheets. The amino acids are each complementary to an amino acid in a second peptide and self-assembles into anti-parallel beta -sheets.A', B'and C'=hydrogen bonding amino acid selected from proton donors and proton acceptors;andA3, A4, B3, B4, C3 and C4=hydrogen bond donor amino acid, a hydrogen bond acceptor amino acid, a positively charged amino acid, a negatively charged amino acid, or a van der Waal's interacting amino acid.    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Composition: The composition further comprises an excipient and stabilizing agent. Preferred Components: The therapeutic agent is selected from drugs, small protein molecules, oligonucleotides, short interfering RNAs (siRNA), micro RNA (miRNA), short hairpin RNA (shRNA), hydrophobic or hydrophilic drug, anti-cancer agent (preferably paclitaxel, ellipticine, camptothecin, doxorubicin or adriamycin), or an oligonucleotide. ACTIVITY - None given.    MECHANISM OF ACTION - None given    ADMINISTRATION - The administration of composition is by oral or intravenous route. No dosage details given.    SPECIFIC COMPOUNDS - 5 Peptides are specifically claimed as peptide (P1) i.e. Gln-Asn-Gln-Asn (SEQ ID NO: 1), Gln-Gln-Asn-Asn (SEQ ID NO: 2), Asn-Ser-Asn-Ser (SEQ ID NO: 3), Asn-Ser-Asn-Ser-Asn (SEQ ID NO: 4), and Asn-Ser-Asn-Ser-Asn-Ser-Asn-Ser (SEQ ID NO: 5). 2 Peptides are specifically claimed as peptide (P2) i.e. Phe-Glu-Phe-Gln-Phe-Asn-Phe-Lys (AC8) (SEQ ID NO: 6) and Phe-Glu-Phe-Gln-Phe-Arg-Phe-Lys.    EXAMPLE - No suitable example given.